New blood test could personalize breast cancer care
NCT ID NCT06762483
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to create a blood test (liquid biopsy) that can detect two key genetic mutations, ESR1 and gBRCA, in patients with a common type of metastatic breast cancer (HR+/HER2-). The test would help doctors choose the most effective treatments without needing a tissue biopsy. Researchers will also build a digital gene library to support this diagnostic approach. The study involves 80 participants and is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- liquid biopsy (blood test)
- What this could lead to
- If successful, this could lead to a simple blood test that helps doctors choose the right treatments for people with metastatic breast cancer, potentially improving outcomes.
- What could go wrong
- This is an early-stage diagnostic study with only 80 participants, so the test may not prove accurate enough for widespread use. It does not test a new treatment, so direct patient benefit is not guaranteed.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER, METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
European Institute of oncology
RECRUITINGMilan, Italy, 20141, Italy
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a common breast cancer drug work equally well in underrepresented groups?
- Can a drug cocktail cure metastatic breast cancer? a trial aims to find out
- PET scan could reveal which breast cancer patients will respond to targeted therapy
- New study aims to catch lymphedema early in breast cancer patients
- New drug targets Hard-to-Treat cancers in japanese patients
- Real-World study tracks palbociclib use in canadian breast cancer patients